Dr. Toni Rinow reports
PIVOT PHARMA ENTERS US CBD MARKET WITH ITS PROPRIETARY CBD PRODUCT LINE
Pivot Pharmaceuticals Inc. has entered into a contract manufacturing and supply agreement with F&B Cosmetics to manufacture Pivot's differentiated portfolio of CBD-based wellness products in the United States.
Pivot will enter the U.S. market in the first quarter of 2020 with its differentiated CBD-based products using Pivot's patented technologies. Pivot recognizes the importance of creating a market-leading brand and Pivot is actively working with Joseph Mimran & Associates to brand and market the Pivot products in North America.
Pivot's ultimate goal is to be a market leader in the emerging phytocannabinoids medical wellness market offering comprehensive science-based solutions of preventive and self-care treatment to the company's customers.
"Pivot's future lies in the successful launch of its differentiated CBD product line using Pivot's patented technologies along with customer acceptance of its superior and proprietary phytocannabinoids products," said Dr. Toni Rinow, chief executive officer of Pivot. "With our team of scientists Pivot is focused on the development of value-added CBD and nutraceutical products. Pivot also embraces the ethical responsibility of offering high-quality, premium branded products. Pivot's superior products when combined with the branding created by Joseph Mimran & Associates positions Pivot to create a portfolio of world-class phytocannabinoid products in the U.S., Europe and Canada."
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals is a science-based, consumer packaged goods cannabis company engaged in the development and commercialization of health and wellness products using innovative, patent-protected drug delivery technologies.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.